OOIR: Observatory of International Research

Papers

(The H4-Index of Biochimica et Biophysica Acta-Reviews on Cancer is 45. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-05-01 to 2026-05-01.)

Article	Citations
The bridging role of neutrophils in the progression of inflammation-induced colorectal cancer	374
Nutrition and dietary restrictions in cancer prevention	238
Modeling bladder cancer in the laboratory: Insights from patient-derived organoids	148
Role of N7-methylguanosine in gastrointestinal tumors: Molecular mechanisms and therapeutic targets	143
Microbial influence on triggering and treatment of host cancer: An intestinal barrier perspective	142
Targeting ferroptosis with flavonoids for cancer therapy: Mechanisms and opportunities	140
VISTA as a context-dependent immune checkpoint: Implications for tumor immunity and autoimmune pathogenesis	133
Tumour cell-induced platelet aggregation in breast cancer: Scope of metal nanoparticles	118
ESR1 activating mutations: From structure to clinical application	89
Targeted drug delivery systems in Lymphoma treatment: Advances and clinical perspectives	88
Unlocking the power of innate lymphoid cell plasticity in the tumor microenvironment: A revolutionary pathway for cancer immunotherapy	82
The role of protein glycosylation in colorectal cancer: From molecular pathways to clinical applications	81
Uveal melanoma modeling in mice and zebrafish	81
Advances in epigenetic modifications and cervical cancer research	78
Towards a better understanding of kidney CANCER: Genetically engineered mouse models and biomarkers insights	77
Spatiotemporal dynamics of the pre-metastatic niche: remodeling of lung microenvironment before breast cancer metastasis and targeted intervention strategies	76
Epigenetic changes associated with Bacillus Calmette-Guerin (BCG) treatment in bladder cancer	71
In what area of biology has a “new” type of cell death been discovered?	71
Decoding the role of FOXP3 in esophageal cancer: Underlying mechanisms and therapeutic implications	68
CCL20-CCR6 signaling in tumor microenvironment: Functional roles, mechanisms, and immunotherapy targeting	68
Detection methods for mitochondrial DNA heteroplasmy and their potential single-cell applications in cancer	67
Fascin-1 in primary liver cancers, perspectives for targeted therapy	65
Mitochondrial metabolism in laryngeal cancer: therapeutic mechanisms and prospects	62
Unveiling anaphylatoxins: Pioneering cancer therapies through complement system insights	62
The VEGF/VEGFR2 system in ovarian cancer: From functional to pharmacological significance	61

Advances and prospects of mRNA vaccines in cancer immunotherapy	61
Dual perspective on autophagy in glioma: Detangling the dichotomous mechanisms of signaling pathways for therapeutic insights	58
Exploring synthetic lethality in cancer therapy: CRISPR-Cas9 technology offers new hope	58
Dysregulated mitochondrial dynamics in cancer: Unlocking new strategies to combat drug resistance	57
Evolution of the MUC1 gene in eutherian mammals as an adaptation responsible for the increasing incidence of cancer in humans	57
Prostate cancer: Molecular aspects, consequences, and opportunities of the multifocal nature	55
Revisiting CHK1 and WEE1 kinases as therapeutic targets in cancer	54
Long non-coding RNAs: Fundamental regulators and emerging targets of cancer stem cells	53
Extracellular vesicles in cancer therapy: Roles, potential application, and challenges	53
Insights into the role of connexins and specialized intercellular communication pathways in breast cancer: Mechanisms and applications	53
Yin yang 1: a potential regulator of immune related diseases and cancer immunity	52
Biomarkers in high grade serous ovarian cancer	51
Targeting lipid metabolism in cancer metastasis	51
S100A8 and S100A9 in Cancer	50
Multiple impacts of Naa10p on cancer progression: Molecular functions and clinical prospects	49
Enhancing the anti-tumor response by combining DNA damage repair inhibitors in the treatment of solid tumors	48
Targeting Cdc20 for cancer therapy	47
Inhibition of nucleotide excision repair proteins associated with cancer chemotherapy	47
Organoids as a new approach in advancing cancer therapies for hematologic malignancies	46
Interleukin-21 as an adjuvant in cancer immunotherapy: Current advances and future directions	46
Mitochondrial dynamics and metabolic attributes regulate function of natural killer cell and infiltration in tumor microenvironment modulating disease progression	45
Organic nanoplatforms for metallodrugs delivery: Current advances in colorectal cancer	45
Recent insights into RNA m5C methylation modification in hepatocellular carcinoma	45
Emerging perspectives on metabolic reprogramming in the microenvironment of ovarian cancer metastasis	45